findmyKOL
Clinical trialNCT06698250RecruitingPhase 2Interventional

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

SponsorAnwaar SaeedEnrollment40Hepatocellular Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HCC).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Upmc Hillman Cancer Center

    Pittsburgh, Pennsylvania, United States

    Anwaar Saeed, MD
    Recruiting
  • Houston Methodist Neal Cancer Center

    Houston, Texas, United States

    Maen Abdelrahim, MD
    Not, yet, recruiting
  • Mays Cancer Center, Ut Health San Antonio

    San Antonio, Texas, United States

    Sukeshi Patel Arora, MD
    Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Durvalumab →Tremelimumab →Zanzalintinib
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
18 Dec 2024
Primary completion
31 Dec 2026
Completion
30 Apr 2027
Last update posted
6 Nov 2025
Registered enrollment
40
Registry id
NCT06698250
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.